POINT Biopharma Global (PNT) 10-Q 12 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 08, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-39311
Entity Registrant Name	POINT BIOPHARMA GLOBAL INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-0800493
Entity Address, Address Line One	4850 West 78th Street
Entity Address, City or Town	Indianapolis
Entity Address, State or Province	IN
Entity Address, Postal Zip Code	46268
City Area Code	647
Local Phone Number	812-2417
Title of 12(b) Security	Common Stock
Trading Symbol	PNT
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		90,121,794
Entity Central Index Key	0001811764
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Amendment Flag	false

Interim Condensed Consolidated

Interim Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 252,825,718	$ 10,546,749
Prepaid expenses and other current assets	6,468,219	1,850,346
Total current assets	259,293,937	12,397,095
Property, plant and equipment	17,901,979	9,797,400
Total assets	277,195,916	22,194,495
Current liabilities
Accounts payable	3,218,234	3,596,634
Accrued liabilities	4,674,266	1,479,041
Income taxes payable	201,629	87,882
Total current liabilities	8,094,129	5,163,557
Deferred tax liability	62,719	0
Mortgage payable, net of debt discount	0	3,550,660
Total liabilities	8,156,848	8,714,217
Commitment and contingencies (note 10)
Stockholders’ equity
Common Stock, par value $0.0001 per share, 430,000,000 authorized, 90,121,794 and 54,647,656 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	9,012	5,465
Additional paid-in capital	314,117,994	26,857,040
Accumulated deficit	(45,087,938)	(13,382,227)
Total stockholders’ equity	269,039,068	13,480,278
Total liabilities and stockholders’ equity	$ 277,195,916	$ 22,194,495

Interim Condensed Consolidate_2

Interim Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common shares, par value (in dollars per share)	$ 0.0001	$ 0.001	$ 0.0001
Common stock, authorized (in shares)	430,000,000		430,000,000
Common stock, shares issued (in shares)	90,121,794	90,121,794	54,647,656
Common stock, shares outstanding (in shares)	90,121,794	90,121,794	54,647,656

Unaudited Interim Condensed Con

Unaudited Interim Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses
Research and development	$ 13,004,649	$ 2,480,064	$ 23,974,809	$ 5,024,980
General and administrative	4,026,666	596,164	7,440,910	2,687,161
Total operating expenses	17,031,315	3,076,228	31,415,719	7,712,141
Loss from operations	(17,031,315)	(3,076,228)	(31,415,719)	(7,712,141)
Other (expenses) income
Finance costs	(6,178)	(2,507)	(11,840)	(2,507)
Foreign currency gain (loss)	1,905	31,485	(32,901)	(33,928)
Total other expenses (income)	(4,273)	28,978	(44,741)	(36,435)
Loss before provision for income taxes	(17,035,588)	(3,047,250)	(31,460,460)	(7,748,576)
Provision for income taxes	(81,044)	0	(245,251)	(73,505)
Net loss	$ (17,116,632)	$ (3,047,250)	$ (31,705,711)	$ (7,822,081)
Net loss per basic and diluted common share:
Basic net loss per common share (in dollars per share)	$ (0.19)	$ (0.06)	$ (0.46)	$ (0.23)
Diluted net loss per common share (in dollars per share)	$ (0.19)	$ (0.06)	$ (0.46)	$ (0.23)
Basic weighted average common shares outstanding (in shares)	90,121,794	54,181,325	68,317,492	33,579,905
Diluted weighted average common shares outstanding (in shares)	90,121,794	54,181,325	68,317,492	33,579,905

Unaudited Interim Condensed C_2

Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Total	Previously Reported	Revision of Prior Period, Adjustment	POINT Biopharma Inc	Common Stock	Common StockPreviously Reported	Common StockRevision of Prior Period, Adjustment	Common StockPOINT Biopharma IncPreviously Reported	Common StockPOINT Biopharma IncRevision of Prior Period, Adjustment	Additional Paid-in Capital	Additional Paid-in CapitalPreviously Reported	Additional Paid-in CapitalRevision of Prior Period, Adjustment	Accumulated Deficit	Accumulated DeficitPreviously Reported	Accumulated DeficitRevision of Prior Period, Adjustment
Beginning balance (in shares) at Dec. 31, 2019					0	0
Beginning balance at Dec. 31, 2019	$ (9,224)	$ (9,224)	$ 0		$ 0	$ 0	$ 0			$ 0	$ 0	$ 0	$ (9,224)	$ (9,224)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares of Common Stock (in shares)					22,710,246
Issuance of shares of Common Stock	3,244,433				$ 2,271					3,242,162			0
Stock-based compensation	660,163									660,163
Net loss	(1,582,834)												(1,582,834)
Ending balance (in shares) at Mar. 31, 2020					22,710,246
Ending balance at Mar. 31, 2020	2,312,538				$ 2,271					3,902,325			(1,592,058)
Beginning balance (in shares) at Dec. 31, 2019					0	0
Beginning balance at Dec. 31, 2019	(9,224)	(9,224)	0		$ 0	$ 0	$ 0			0	0	0	(9,224)	(9,224)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(7,822,081)
Ending balance (in shares) at Sep. 30, 2020					54,647,656
Ending balance at Sep. 30, 2020	18,889,442				$ 5,465					26,715,282			(7,831,305)
Beginning balance (in shares) at Mar. 31, 2020					22,710,246
Beginning balance at Mar. 31, 2020	2,312,538				$ 2,271					3,902,325			(1,592,058)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares of Common Stock (in shares)					29,724,514
Issuance of shares of Common Stock	8,009,321				$ 2,973					8,006,348
Stock-based compensation	554,888									554,888
Net loss	(3,191,997)												(3,191,997)
Ending balance (in shares) at Jun. 30, 2020					52,434,760
Ending balance at Jun. 30, 2020	7,684,750				$ 5,244					12,463,561			(4,784,055)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares of Common Stock (in shares)					2,212,896
Issuance of shares of Common Stock	11,321,625				$ 221					11,321,404
Issuance of warrants	2,526,320									2,526,320
Stock-based compensation	403,997									403,997
Net loss	(3,047,250)												(3,047,250)
Ending balance (in shares) at Sep. 30, 2020					54,647,656
Ending balance at Sep. 30, 2020	$ 18,889,442				$ 5,465					26,715,282			(7,831,305)
Beginning balance (in shares) at Dec. 31, 2020	54,647,656				54,647,656	0	54,647,656	15,233,884	15,233,884
Beginning balance at Dec. 31, 2020	$ 13,480,278	13,480,278	0		$ 5,465	$ 0	$ 5,465	$ 15,234	$ (15,234)	26,857,040	26,847,271	9,769	(13,382,227)	(13,382,227)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares of Common Stock in connection with exercise of warrants (in shares)					2,869,799
Issuance of shares of Common Stock in connection with exercise of warrants	20,000,000				$ 287					19,999,713
Issuance of shares of Common Stock in connection with stock option exercises (in shares)					64,570
Issuance of shares of Common Stock in connection with stock option exercises	450,000				$ 6					449,994
Stock-based compensation	477,245									477,245
Net loss	(5,784,421)												(5,784,421)
Ending balance (in shares) at Mar. 31, 2021					57,582,025
Ending balance at Mar. 31, 2021	$ 28,623,102				$ 5,758					47,783,992			(19,166,648)
Beginning balance (in shares) at Dec. 31, 2020	54,647,656				54,647,656	0	54,647,656	15,233,884	15,233,884
Beginning balance at Dec. 31, 2020	$ 13,480,278	$ 13,480,278	$ 0		$ 5,465	$ 0	$ 5,465	$ 15,234	$ (15,234)	26,857,040	$ 26,847,271	$ 9,769	(13,382,227)	$ (13,382,227)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares of Common Stock (in shares)					800,000
Issuance of shares of Common Stock in connection with stock option exercises (in shares)					64,570
Net loss	$ (31,705,711)
Ending balance (in shares) at Sep. 30, 2021	90,121,794				90,121,794
Ending balance at Sep. 30, 2021	$ 269,039,068				$ 9,012					314,117,994			(45,087,938)
Beginning balance (in shares) at Mar. 31, 2021					57,582,025
Beginning balance at Mar. 31, 2021	28,623,102				$ 5,758					47,783,992			(19,166,648)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares of Common Stock, net of direct and incremental costs in connection with the Business Combination (refer to Note 3) (in shares)					32,539,769
Issuance of shares of Common Stock, net of direct and incremental costs in connection with the Business Combination (refer to Note 3)	264,565,421				$ 3,254					264,562,167
Stock-based compensation	1,106,457									1,106,457
Net loss	$ (8,804,658)												(8,804,658)
Ending balance (in shares) at Jun. 30, 2021	90,121,794			90,121,794	90,121,794
Ending balance at Jun. 30, 2021	$ 285,490,322				$ 9,012					313,452,616			(27,971,306)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares of Common Stock (in shares)					0
Issuance of shares of Common Stock, net of direct and incremental costs in connection with the Business Combination (refer to Note 3)	317,261									317,261
Stock-based compensation	348,117									348,117
Net loss	$ (17,116,632)												(17,116,632)
Ending balance (in shares) at Sep. 30, 2021	90,121,794				90,121,794
Ending balance at Sep. 30, 2021	$ 269,039,068				$ 9,012					$ 314,117,994			$ (45,087,938)

Unaudited Interim Condensed C_3

Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity (Parentheticals) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statement of Stockholders' Equity [Abstract]
Cost and fees on issuance of common shares	$ 324,555	$ 0	$ 324,555

Unaudited Interim Condensed C_4

Unaudited Interim Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net loss:	$ (31,705,711)	$ (7,822,081)
Adjustments to reconcile net loss to net cash used in operating activities:
Deferred income taxes	62,719	0
Stock-based compensation expense	1,931,819	1,619,048
Amortization of debt issuance costs	11,840	2,507
Changes in operating assets and liabilities
Prepaid expenses and other current assets	(4,617,873)	(82,611)
Accounts payable	(378,400)	1,957,578
Accrued liabilities	3,077,699	458,988
Income taxes payable	113,747	73,505
Amount due to related party within accrued liabilities	117,526	7,233
Net cash used in operating activities	(31,386,634)	(3,785,833)
Cash flows from investing activities
Purchase of property, plant and equipment	(8,104,579)	(6,090,918)
Net cash used in investing activities	(8,104,579)	(6,090,918)
Cash flows from financing activities
Issuance of common stock and warrants to purchase common stock of POINT Biopharma Inc.		25,426,254
Costs and fees on issuance of Common Stock	0	(324,555)
Borrowings on mortgage payable, net of debt discount	0	3,545,306
Repayment of mortgage payable	(3,562,500)	0
Issuance of shares of Common Stock in connection with exercise of warrants	20,000,000
Issuance of shares of Common Stock in connection with stock option exercises	450,000
Issuance of shares of Common Stock in connection with the Business Combination (see note 3), net of costs incurred by RACA and direct and incremental costs paid	264,882,682
Net cash provided by financing activities	281,770,182	28,647,005
Net increase in cash and cash equivalents	242,278,969	18,770,254
Cash and cash equivalents, beginning of period	10,546,749	0
Cash and cash equivalents, end of period	252,825,718	18,770,254
Supplemental disclosure of cash flow information:
Cash paid for income taxes	(68,785)	0
Cash paid for interest on mortgage payable	$ (92,338)	$ 0

Nature of business

Nature of business	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of business	Nature of business Formation and organization POINT Biopharma Global Inc., together with its consolidated subsidiaries (the “Company”), is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. On September 18, 2019, POINT Theranostics Inc. was incorporated under the General Corporation Law of the State of Delaware (the "DGCL") and amended its name to “POINT Biopharma Inc.” on November 22, 2019. On September 30, 2021, following the Business Combination (as defined below), POINT Biopharma Inc. became a wholly-owned subsidiary of POINT Biopharma Global Inc. Under the terms of the Business Combination Agreement (as defined below), shareholders of POINT Biopharma Inc. received approximately 3.59 shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”) in exchange for each common share of Point Biopharma Inc. Also in connection with the closing of the Business Combination, RACA (as defined below) consummated the sale of an aggregate of 16,500,000 shares of Class A common stock, par value $0.0001 per share, of RACA (“Class A Common Stock”) in a private placement at a price of $10.00 per share, for aggregate gross proceeds of $165,000,000 (“PIPE Financing”). In accordance with the terms of the Business Combination Agreement, upon the closing of the Business Combination (as defined below), each share of Class A Common Stock and each share of Class B common stock, par value $0.0001 per share, of RACA (“Class B Common Stock”) was converted into one share of Common Stock of the Company. For additional information on the Business Combination, please see Note 3. The Company was founded on a mission to make radioligand therapy applicable to more cancers and available to more people, thereby improving the lives of cancer patients and their families everywhere. The Company has four wholly-owned subsidiaries, POINT Biopharma Inc., POINT Biopharma USA Inc. and West 78 th Street, LLC, each located in the USA, and POINT Biopharma Corp., located in Canada. The Company’s headquarters is located at 4850 West 78 th Street, Indianapolis, Indiana, 46268.

Summary of significant accounti

Summary of significant accounting policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Basis of presentation The accompanying unaudited interim condensed unaudited condensed financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 270, Interim Reporting and include the accounts of the Company and its wholly-owned subsidiaries, POINT Biopharma Inc., POINT Biopharma Corp., POINT Biopharma USA, Inc. and West 78 th Street, LLC, for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the balances and results for the periods presented. Except as described below, the accounting policies and methods of computation applied in the unaudited interim condensed consolidated financial statements and related notes contained therein are consistent with those applied by the Company in its audited consolidated financial statements as of and for the year ended December 31, 2020 contained in our Registration Statement on Form S-1 filed with the SEC on July 30, 2021(the “2020 Financial Statements”). These unaudited interim condensed consolidated financial statements should be read in conjunction with the 2020 Financial Statements. These unaudited interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with the provisions of ASC Topic 205-40, Presentation of Financial Statements—Going Concern on the basis that the Company will continue as a going concern. Impact of COVID-19 The COVID-19 pandemic, which was declared by the World Health Organization as a pandemic in March 2020 and has spread worldwide, has caused many governments to implement measures to slow the spread of the outbreak through quarantines, travel restrictions, heightened border security and other measures. The impact of this pandemic has been, and will likely continue to be, extensive in many aspects of society, which has resulted, and will likely continue to result, in significant disruptions to the global economy as well as businesses and capital markets around the world. The future progression of the pandemic and its effects on the Company’s business and operations are uncertain. In response to public health directives and orders and to help minimize the risk of the virus to employees, the Company has taken precautionary measures, including implementing work-from-home policies for certain employees. The impact of the virus, including work-from-home policies, may negatively impact productivity, disrupt the Company’s business, and delay its preclinical research and clinical trial activities and its development program timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company’s ability to conduct its business in the ordinary course. Specifically, the Company may not be able to fulfill enrollment expectations on its planned timeline or visit clinics to conduct on-site monitoring due to disruptions at its clinical trial sites. The Company is currently unable to predict when potential disruptions to its clinical programs resulting from the pandemic will resolve. Other impacts to the Company’s business may include temporary closures of its suppliers and disruptions or restrictions on its employees’ ability to travel. Any prolonged material disruption to the Company’s employees or suppliers could adversely impact the Company’s preclinical research and clinical trial activities, financial condition and results of operations, including its ability to obtain financing. The Company is monitoring the ongoing impact of the COVID-19 pandemic on its business and the unaudited interim condensed consolidated financial statements. To date, the Company has not experienced any material business disruptions or incurred any impairment losses in the carrying values of its assets as a result of the pandemic, and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these unaudited interim condensed consolidated financial statements. Risks and uncertainties The Company has incurred significant net losses since inception and, prior to the Business Combination, has funded operations through equity financings. Operating losses and negative cash flows are expected to continue for the foreseeable future. As losses continue to be incurred, the Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, regulatory approval of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of the COVID-19 coronavirus, the ability to secure additional capital to fund operations and commercial success of its product candidates. Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. Use of estimates The preparation of the unaudited interim condensed consolidated financial statements requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements, and the reported amounts of expenses for the periods presented. Significant estimates and assumptions reflected in these unaudited interim condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuations of stock options and warrants. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Recent accounting pronouncements not yet effective Debt with Conversion and Other Options The FASB has issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible instruments, such as convertible debt or convertible preferred stock, by eliminating two potential methods in accounting for the embedded conversion feature. The standard also removes certain conditions previously used to evaluate whether a freestanding financial instrument, or certain types of embedded features, are considered to be settled in the issuer’s own equity. Finally, ASU 2020-06 requires that an entity use the if-converted method in calculating the effects of convertible instruments on diluted earnings per share, with one limited exception. The amendments in this ASU are effective for the Company for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than for fiscal years beginning after December 15, 2020. The Company does not expect a material impact to its consolidated financial statements as a result of this guidance. Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options The FASB has issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2021-04 provides guidance that an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. The standard also provides guidance on how an entity should measure and recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified. The amendments in this ASU are effective for the Company for fiscal years beginning after December 15, 2021. Early adoption is permitted for all entities, including adoption in an interim period. The Company does not expect a material impact to its consolidated financial statements as a result of this guidance.

Business Combination

Business Combination	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Business Combination	Business Combination On March 15, 2021, POINT Biopharma Inc. entered into a definitive business combination agreement (the “Business Combination Agreement”) with Therapeutics Acquisition Corp., d/b/a Research Alliance Corp. I (“RACA”), a special purpose acquisition company sponsored by RA Capital Management, that was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. On June 30, 2021, (the “Closing Date”), Bodhi Merger Sub, Inc. (“Bodhi Merger Sub”), a wholly-owned subsidiary of RACA, merged with and into POINT Biopharma Inc. (the “Business Combination”), with POINT Biopharma Inc. as the surviving company in the Business Combination and, after giving effect to such Business Combination, POINT Biopharma Inc. became a wholly-owned subsidiary of RACA. RACA was then renamed “POINT Biopharma Global Inc.” In accordance with the terms of the Business Combination Agreement, upon the closing of the Business Combination: (i) each share and vested equity award of POINT Biopharma Inc. outstanding as of immediately prior to the Closing Date was converted into shares of Common Stock of the Company or comparable vested equity awards that are exercisable for shares of Common Stock of the Company, based on an implied vested equity value of $585,000,000 (which is equal to a conversion ratio of approximately 3.59-for-1); and (ii) all unvested equity awards of POINT Biopharma Inc. were converted into comparable equity awards that are exercisable for shares of Common Stock of the Company, determined based on the same conversion ratio at which the vested equity awards are converted into shares of Common Stock of the Company; and (iii) each share of RACA Class A Common Stock and each share of RACA Class B Common Stock that was issued and outstanding immediately prior to the Closing Date became one share of Common Stock of the Company. In connection with the Business Combination, the Company consummated the PIPE Financing, pursuant to which it received $165.0 million in exchange for 16,500,000 shares of Common Stock of the Company. After giving effect to the Business Combination, there were 90,121,794 shares of Common Stock issued and outstanding. We accounted for the Business Combination as a reverse recapitalization, in accordance with GAAP. POINT Biopharma Inc. is treated as the accounting acquirer (legal acquiree), while RACA is the accounting acquiree (legal acquirer) for financial reporting purposes. This determination is primarily based on the fact that the former POINT Biopharma Inc. shareholders retained a majority of the voting power of the Company and comprise a majority of the governing body of the Company, and the former POINT Biopharma Inc. senior management comprise substantially all of the senior management of the Company. Accordingly, for accounting purposes, the Business Combination is treated as the equivalent of POINT Biopharma Inc. issuing shares for the net assets of RACA, accompanied by a recapitalization. The net assets of RACA are stated at historical costs. No goodwill or other intangible assets is recorded. In connection with the Business Combination, the Company incurred underwriting fees and other costs considered to be direct or incremental to the proceeds raised in connection with the Business Combination and PIPE Financing totaling approximately $21.9 million, consisting of costs incurred by RACA prior to the completion of the Business Combination as well as investment banker, legal, audit, tax, accounting and listing fees. These amounts are reflected within additional paid-in capital in the interim condensed consolidated balance sheet as of September 30, 2021. Summary of net proceeds The following table summarizes the elements of the net proceeds from the Business Combination: Recapitalization Cash - RACA Trust and cash (net of redemptions) 121,770,367 Cash - PIPE Financing 165,000,000 Less: Underwriting fees, costs incurred by RACA and other direct and incremental costs, each paid prior to September 30, 2021 (21,887,685) Net proceeds from the Business Combination, net of costs incurred by RACA and direct and incremental costs paid per the statement of cash flows 264,882,682 The net proceeds noted above exclude approximately $4.7 million in transaction costs that were not considered direct and incremental to the raising of capital. These costs consist of corporate expenses in the normal course of business comprised of accounting, consulting, insurance and board retainer fees. These costs were recorded as incurred in accordance with the nature of the services received. During the three months ended September 30, 2021, the Company updated its estimate for certain accrued transaction costs resulting in a reduction in total transaction costs by approximately $0.3 million which has been recorded through additional paid in capital. Summary of shares of Common Stock issued The following table summarizes the number of shares of Common Stock outstanding immediately following the consummation of the Business Combination: Number of RACA Class A and Class B shares outstanding prior to the Business Combination 16,039,769 Class A shares issued pursuant to the PIPE Financing 16,500,000 Business Combination and PIPE Financing shares as converted into Common Stock 32,539,769 Conversion of POINT Biopharma Inc. common shares into Common Stock 57,582,025 Total shares of POINT Biopharma Global Inc. Common Stock outstanding immediately following the Business Combination 90,121,794

Prepaid expenses and other curr

Prepaid expenses and other current assets	9 Months Ended
	Sep. 30, 2021
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid expenses and other current assets	Prepaid expenses and other current assets Prepaid expenses and other current assets consisted of the following: As of September 30, 2021 As of December 31, 2020 $ $ Insurance 3,103,769 — Prepaid clinical trial expenses 2,548,625 1,763,731 Deposit on production equipment 594,143 — Canadian harmonized sales tax receivable 48,621 58,982 Other 173,061 27,633 Total 6,468,219 1,850,346

Accrued expenses

Accrued expenses	9 Months Ended
	Sep. 30, 2021
Accrued Liabilities, Current [Abstract]
Accrued expenses	Accrued expenses Accrued liabilities consisted of the following: As of September 30, 2021 As of December 31, 2020 $ $ Accrued personnel costs 2,142,189 540,292 Accrued research and development costs 1,992,670 597,994 Accrued costs for purchases of property, plant and equipment 112,236 — Accrued corporate legal fees and other professional services 253,221 210,099 Other accrued costs 173,950 130,656 Total 4,674,266 1,479,041

Property, plant and equipment,

Property, plant and equipment, net	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment, net consisted of the following: As of September 30, 2021 As of December 31, 2020 $ $ Property in development 15,816,792 9,797,400 Machinery and equipment 1,395,544 — Furniture and fixtures 591,652 — Computer equipment 97,991 — Total 17,901,979 9,797,400

Mortgage payable

Mortgage payable	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Mortgage payable	Mortgage payable On July 10, 2020, the Company obtained a mortgage loan in the amount of $3,562,500 (the “Mortgage”) for the purpose of purchasing land and a building with approximately 80,000 squar e-feet located in Indianapolis, Indiana (the “Property”). The Mortgage was collateralized by a first charge over the Property. As part of the financing the Company incurred $17,194 of costs and fees from the lender that were capitalized and recorded as finance costs over the life of the Mortgage. On July 29, 2021, the Mortgage on the manufacturing facility in Indianapolis, Indiana was repaid and the related mortgage on the Company's facility in Indianapolis, Indiana was released. Prior to its repayment, the Mortgage bore interest at 2.85% plus a minimum rate of 1-month LIBOR, subject to a LIBOR floor of 0.25%. The Mortgage required quarterly interest payments, which commenced on October 1, 2020, with the principal amount originally due at maturity on January 10, 2022. For the three months ended September 30, 2021, the Company recorded $8,590 in interest costs (September 30, 2020 — $25,462) which have been capitalized within property, in development, and $6,178 in amortization of debt issuance costs (September 30, 2020 — $2,507) through finance costs. For the nine months ended September 30, 2021, the Company recorded $63,195 in interest costs (September 30, 2020 — $25,462) which have been capitalized within property, in development, and $11,840 in amortization of debt issuance costs (September 30, 2020 — $2,507) through finance costs.

Stockholders' equity

Stockholders' equity	9 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Stockholders' equity	Stockholders’ equity The Company is authorized to issue 430,000,000 shares of Common Stock, with a par value of $0.0001 per share,as well as 20,000,000 of shares of preferred stock, with a par value of $0.0001 per share (“Preferred Stock”). The figures below are presented giving effect to a retroactive application of the Business Combination which resulted in a conversion of the previous POINT Biopharma Inc. common shares to shares of Common Stock of the Company at a conversion ratio of approximately 3.59:1. The par value of previous POINT Biopharma Inc. common shares was $0.001. See Note 3 for additional details. During the three months ended September 30, 2021, there were no issuances of Common Stock. During the nine months ended September 30, 2021, the Company (a) issued 32,539,769 shares of Common Stock in connection with the Business Combination and PIPE Financing (see Note 3) and (b) issued 800,000 shares of common stock of POINT Biopharma Inc. (exchanged for 2,869,799 shares of Common Stock) in connection with the exercise of warrants and 18,000 shares of common stock of POINT Biopharma Inc. (exchanged for 64,570 shares of Common Stock) in connection with the exercise of stock options issued to a non-employee consultant, resulting in total cash proceeds of $20,450,000. As of September 30, 2021, the number of total issued and outstanding shares of Common Stock is 90,121,794 (December 31, 2020 – 54,647,656). As of September 30, 2021, there were no issued and outstanding shares of Preferred Stock (December 31, 2020 — nil). Each share of Common Stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, if any, as may be declared by the Company’s board of directors. During the nine months ended September 30, 2021, no cash dividends had been declared or paid by the Company (September 30, 2020 — $nil). The Company’s board of directors has the authority to issue shares of Preferred Stock from time to time on terms it may determine, to divide shares of Preferred Stock into one or more series and to fix the designations, preferences, privileges, and restrictions of Preferred Stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent permitted by the DGCL. During the nine months ended September 30, 2021, no shares of Preferred Stock have been issued by the Company (September 30, 2020 — nil).

Stock-based compensation

Stock-based compensation	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-based compensation	Stock-based compensation In March 2020, the board of directors of POINT Biopharma Inc. approved the 2020 Equity Incentive Plan (the “2020 EIP”). The 2020 EIP provided for the granting of incentive and nonqualified stock options, stock appreciation rights, restricted stock units, performance awards and other stock-based awards to employees, directors, and consultants of POINT Biopharma Inc. Effective as of June 30, 2021, in connection with the Business Combination, the Company’s board of directors adopted the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (the “2021 EIP”) to replace the 2020 EIP and allow the Company to grant equity and equity-based incentive awards to officers, employees, non-employee directors and consultants of the Company. Upon the closing of the Business Combination, the Company assumed the outstanding equity awards under the 2020 EIP and each outstanding option to acquire common shares of POINT Biopharma Inc. (whether vested or unvested) under the 2020 EIP was substituted with a substantially equivalent option to acquire shares of Common Stock of the Company based on the conversion ratio for the POINT Biopharma Inc. common shares in the Business Combination and remains outstanding under the 2020 EIP. No further grants may be made under the 2020 EIP. The Company concluded that the replacement stock options issued in connection with the Business Combination did not require accounting for effects of the modification under the ASC 718 – Compensation – Stock Compensation (“ASC 718”) as it was concluded that (a) the fair value of the modified award is the same as the fair value of the original award immediately before the original award was modified, (b) there are no changes to the vesting conditions of the award, and (c) there is no change to the classification of the award. The Company recorded $222,135 to research and development expense and $125,982 to general and administrative expenses for stock-based compensation for the three months ended September 30, 2021 (September 30, 2020 — $nil to research and development expense and $403,997 to general and administrative expenses). The Company recorded $1,650,804 to research and development expense and $281,015 to general and administrative expenses for stock-based compensation for the nine months ended September 30, 2021 (September 30, 2020 — $nil to research and development expense and$1,619,048 to general and administrative expenses). The Company did not recognize a tax benefit related to stock-based compensation expense during the nine months ended September 30, 2021, as the Company had net operating losses carryforwards and recorded a valuation allowance against the deferred tax asset. The following table summarizes the activity relating to the Company’s stock options. The below stock option figures are presented giving effect to a retroactive application of the Business Combination which resulted in a replacement of the previous POINT Biopharma Inc. stock options with stock options of the Company, as described above, at a conversion ratio of approximately 3.59:1. In addition, the exercise price for each replacement stock option is also adjusted using the ratio of approximately 3.59:1. See Note 3 for additional details: Number of Weighted Weighted- Outstanding as of December 31, 2020 2,364,010 2.88 Granted 1,363,683 8.08 Exercised (64,570) 6.97 Forfeited (36,872) 7.01 Outstanding as of September 30, 2021 3,626,251 4.72 5.4 Vested and expected to vest as of September 30, 2021 3,626,251 4.72 5.4 Options exercisable as of September 30, 2021 985,145 4.51 6.3 During the three months ended September 30, 2021, 1,004,959 stock options were granted to employees and directors of the Company, with a weighted average grant date fair value of $4.697. The vesting terms of these options are such that 25% of the options vest on the one-year anniversary of the date of grant and the remaining 75% of such stock options vest ratably over the remaining three years. During the nine months ended September 30, 2021, 1,363,683 stock options were granted, including the 1,004,959 stock options discussed above as well as 358,724 stock options granted to a non-employee consultant of the Company, with a weighted average grant date fair value of $3.885. The vesting terms of the grant to the non-employee consultant were such that 25% of the options vested immediately upon grant, 10% of the options were initially to vest in a year following the grant and the remaining options were initially to vest based on certain performance milestones. Upon completion of the Business Combination, the remaining 269,043 unvested stock options immediately vested and all remaining unrecognized stock-based compensation expense associated with these stock options was recorded. During the three months ended September 30, 2020, 394,595 stock options were granted to employees and non-employee directors of the Company, with a weighted average grant date fair value of $3.335. 125,553 of such stock options vesting in full upon ninety days after the grant date and the remaining stock options are vesting as to 25% of the options on the one-year anniversary of the date of grant with the remaining 75% of such stock options vesting ratably over the remaining three years. During the nine months ended September 30, 2020, 2,129,048 stock options were granted to employees and non-employee directors of the Company, including the 394,595 stock options discussed above as well as 1,734,453 stock options granted to employees and non-employee consultants of the Company, with a weighted average grant date fair value of $0.701. The vesting terms of the 1,734,453 stock options granted to employees and non-employee consultants of the Company are such that 25% of the options vest on the one-year anniversary of the date of grant and the remaining 75% of such stock options vest ratably over the remaining three years. The following table presents the assumptions used in the Black-Scholes-Merton option-pricing model to determine the grant date fair value of stock options granted: Three months ended September 30, 2021 Three months ended September 30, 2020 Nine months ended September 30, 2021 Nine months ended September 30, 2020 Risk-free interest rate 0.664% 0.184% - 0.249% 0.664% - 0.716% 0.184% - 0.504% Expected term (in years) 4.25 3.08 - 4.25 4.25 - 5.38 3.08 - 4.25 Expected volatility 73% 65% 65% - 73% 65% Expected dividend yield —% —% —% —% During the nine months ended September 30, 2021, a non-employee consultant of the Company exercised 64,570 stock options with an intrinsic value of $nil, resulting in the issuance of 64,570 shares of Common Stock for cash proceeds of $450,000. As of September 30, 2021, the unrecognized stock-based compensation expense related to unvested stock options, was $5,486,152 and the estimated weighted average remaining vesting period was 2.6 years.

Commitments and contingencies

Commitments and contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies Property, in development commitment The Company entered into agreements for the engineering design and modification of the property, in development. As of September 30, 2021, the Company is committed to future payments of approximately $4.1 million, relating to the construction and retrofit of the building, which are due before the expected completion in fiscal year 2021. During the three and nine months ended September 30, 2021, approximately $0.8 million and $5.7 million, respectively has been recorded within property, plant and equipment in connection with these agreements (three and nine months ended September 30, 2020 – $2.3 million and $2.4 million, respectively). Clinical trial and commercial commitments The Company in the normal course of business enters into various services and supply agreements in connection with its clinical trials to ensure the supply of certain product and product lines during the Company’s clinical phase. These agreements often have minimal purchase commitments and generally terminate upon the termination of the clinical trial. Minimum purchase commitments under these agreements include individual commitments up to $3.8 million. Aggregate remaining minimum commitments amount to approximately $7.4 million with payments ranging from three The Company also has a supply agreement with a third party to purchase certain products for use in the Company’s full scale production process. The Company is committed to purchase a minimum quantity of product in the amount of approximately $49.5 million ($62.9 million CAD) over the contract term. The purchase commitments are contingent upon the completion of certain milestones by the third-party supplier. The Company recorded $nil and $nil, respectively, in connection with this agreement during the three and nine months ended September 30, 2021 (three and nine months ended September 30, 2020 - $nil and $nil, respectively). The Company also has an agreement with a third party to provide certain services in connection with the Company’s SPLASH clinical phase study. The agreement expires on the date of the completion or termination of the clinical trial. The remaining minimum purchase commitment under this agreement is approximately $47.7 million with payments that range from one License agreements The Company in the normal course of business enters into license and sublicense agreements in connection with its clinical trials and product development. For additional details of the Company’s license agreements, see Note 12 in the 2020 Financial Statements. On June 30, 2021, the Company entered into a license agreement with the Belgian Nuclear Research Centre (“SCK-CEN”). Under the SCK-CEN Agreement, the Company was granted a worldwide, royalty-bearing, non-exclusive, sublicensable license under SCK-CEN’s patent rights to develop, make, have made, use and import no carrier-added Lu-177 using SCK-CEN Technology. The Company is obligated to make aggregate milestone payments to SCK-CEN of up to $127,000 (€110,000) upon the achievement of certain technology implementation milestones. The Company is also obligated to make aggregate minimum royalty payments of $8,200,000 (€7,120,000) over the course of 8 years commencing in 2023 with an annual cap of €6,300,000 over the same term. The Company did not record any costs in connection to this license agreement during the three and nine months ended September 30, 2021. On September 24, 2021, POINT Biopharma Inc. entered into a third amendment (the “Third Amendment”) to that certain Exclusive Sublicense Agreement, dated April 2, 2020, between POINT Biopharma Inc. and Bach Biosciences, LLC, ("Bach Biosciences") as amended by the First Amendment to Exclusive Sublicense Agreement, dated April 14, 2020, and the Second Amendment to Exclusive Sublicense Agreement, dated January 5, 2021 (collectively, the “Sublicense Agreement”). The Sublicense Agreement grants to POINT Biopharma Inc. an exclusive, sublicensable, worldwide license under Bach Biosciences’ patent rights to use, develop, manufacture and commercialize any products arising from the licensed technology. Pursuant to the Third Amendment, POINT Biopharma Inc. exercised its option (the “Commercialization Option”) under the Sublicense Agreement to acquire a worldwide exclusive, royalty bearing license to commercialize any products and processes from uses of patent rights for FAP-targeted radiopharmaceuticals. The Third Amendment also amended the Sublicense Agreement to provide the Company with the first option (the “Invention Option”) to acquire a worldwide exclusive royalty bearing license to Bach Biosciences’ patent rights, materials and know-how with respect to new inventions directed to FAP-targeted radiopharmaceuticals. As partial consideration for the exercise of the Commercialization Option and the grant of the Invention Option under the Third Amendment, POINT Biopharma Inc. paid, upon execution of the Sublicense Agreement, an option exercise fee of $3,250,000. POINT Biopharma Inc. is also required to make regular quarterly contributions up to a specified amount to Bach Biosciences’ specified research and development until June 1, 2022 and October 1, 2022, in each case, commencing on October 1, 2021. The Company recorded research and development expenses in connection to the Third Amendment of $3,250,000 during the three and nine months ended September 30, 2021 The Company recorded research and development expenses in connection to its license agreements of approximately $4.0 million and $4.9 million during the three and nine months ended September 30, 2021, respectively, (three and nine months ended September 30, 2020 – $0.4 million and $1.4 million, respectively).

Net loss per share

Net loss per share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net loss per share	Net loss per share Basic loss earnings per share is computed by dividing the loss available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. Diluted loss per share is computed by dividing loss available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive securities had been issued, using the treasury stock method. The below figures are presented giving effect to a retroactive application of the Business Combination which resulted in a conversion of the previous POINT Biopharma Inc. common shares to shares of Common Stock of the Company at a conversion ratio of approximately 3.59:1. See Note 3. Three months ended September 30, 2021 Three months ended September 30, 2020 Nine months ended September 30, 2021 Nine months ended September 30, 2020 Net loss attributable to common stockholders 17,116,632 3,047,250 31,705,711 7,822,081 Weighted-average common shares outstanding-basic and diluted 90,121,794 54,181,325 68,317,492 33,579,905 Net loss per share attributable to common stockholders-basic and diluted $ 0.19 $ 0.06 $ 0.46 $ 0.23 The Company’s potentially dilutive securities, which include stock options and warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of shares of Common Stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company has operations in both the United States and Canada, as such it is subject to tax in both countries. The income tax expense for the three months ended September 30, 2021 and September 30, 2020 was $81,044 and nil respectively. The income tax expense for the nine months ended September 30, 2021 and September 30, 2020 was $245,251 and $73,505 respectively. As of September 30, 2021, the Company had no uncertain tax positions (December 31, 2020 — $nil). The Company files income tax returns in the US federal, certain state, and Canada with varying statutes of limitations. The Company is not currently subject to tax examinations by any taxing jurisdiction. However, in the event of any such examination of its tax years 2019 and 2020, there may or may not be an impact on the Company’s net operating loss carryforwards and credits. The Company does not anticipate that any potential tax adjustments resulting from such examinations would have a significant impact on its financial position or results of operations. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was passed into law. The CARES Act includes several significant business tax provisions including modification to the taxable income limitation for utilization of net operating losses incurred in 2019 and 2020, an increase to the limitation on deductibility of certain business interest expense, bonus depreciation for purchases of qualified improvement property and special deductions on certain corporate charitable contributions. The Company analyzed the provisions of the CARES Act and determined there was no impact to its income tax provision for the three and nine months ended September 30, 2021 and 2020.

Related party transactions

Related party transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related party transactions	Related party transactions The Company recognized expenses in connection with related party transactions in the unaudited condensed consolidated statements of operations as follows: Three months ended September 30, 2021 Three months ended September 30, 2020 Nine months ended September 30, 2021 Nine months ended September 30, 2020 $ $ $ $ Stock-based compensation for consulting arrangement — — — 1,109,776 Consulting fees to stockholder — 12,029 — 172,720 Consulting fees on business activities to Board member 143,668 29,782 227,546 86,151 Reimbursement to Board member for occupancy costs 18,285 5,564 55,104 5,564 Total 161,953 47,375 282,650 1,374,211 Transactions with related parties are in the normal course of operations and have been measured at their agreed upon exchange amount. During the nine months ended September 30, 2020, the Company issued stock options to shareholders of a related party in exchange primarily for legal and financial consulting services. No amounts are owing in respect of these services as of September 30, 2021. During the nine-month periods ended September 30, 2021 and 2020, the Company received consulting services for research and development from a Board member, for which $117,526 is recorded within accrued liabilities as of September 30, 2021. In addition, during the nine months ended September 30, 2020, the Company received consulting services for manufacturing planning from a stockholder. No amounts are owing in respect of these services as of September 30, 2021. The Company currently has a lease arrangement in place with a Board member for the use of office space. The arrangement does not have a defined contractual lease term and is payable monthly. The Company has applied the short-term lease exemption under ASC Topic 842, Leases to this arrangement and is recording the lease payments of approximately $6,000 monthly as rent expense.

Subsequent events

Subsequent events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent events	Subsequent eventsFor the Company’s unaudited interim condensed consolidated financial statements as of and for the three and nine months ended September 30, 2021, it evaluated subsequent events through November 12, 2021, the date on which those unaudited interim condensed consolidated financial statements were issued. The Company concluded that there were no such events through November 12, 2021.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying unaudited interim condensed unaudited condensed financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 270, Interim Reporting and include the accounts of the Company and its wholly-owned subsidiaries, POINT Biopharma Inc., POINT Biopharma Corp., POINT Biopharma USA, Inc. and West 78 th Street, LLC, for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the balances and results for the periods presented. Except as described below, the accounting policies and methods of computation applied in the unaudited interim condensed consolidated financial statements and related notes contained therein are consistent with those applied by the Company in its audited consolidated financial statements as of and for the year ended December 31, 2020 contained in our Registration Statement on Form S-1 filed with the SEC on July 30, 2021(the “2020 Financial Statements”). These unaudited interim condensed consolidated financial statements should be read in conjunction with the 2020 Financial Statements.
Going Concern	These unaudited interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with the provisions of ASC Topic 205-40, Presentation of Financial Statements—Going Concern on the basis that the Company will continue as a going concern.
Risks and uncertainties	Risks and uncertainties The Company has incurred significant net losses since inception and, prior to the Business Combination, has funded operations through equity financings. Operating losses and negative cash flows are expected to continue for the foreseeable future. As losses continue to be incurred, the Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, regulatory approval of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of the COVID-19 coronavirus, the ability to secure additional capital to fund operations and commercial success of its product candidates. Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
Use of estimates	Use of estimates The preparation of the unaudited interim condensed consolidated financial statements requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements, and the reported amounts of expenses for the periods presented. Significant estimates and assumptions reflected in these unaudited interim condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuations of stock options and warrants. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
Recent accounting pronouncements not yet effective	Recent accounting pronouncements not yet effective Debt with Conversion and Other Options The FASB has issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible instruments, such as convertible debt or convertible preferred stock, by eliminating two potential methods in accounting for the embedded conversion feature. The standard also removes certain conditions previously used to evaluate whether a freestanding financial instrument, or certain types of embedded features, are considered to be settled in the issuer’s own equity. Finally, ASU 2020-06 requires that an entity use the if-converted method in calculating the effects of convertible instruments on diluted earnings per share, with one limited exception. The amendments in this ASU are effective for the Company for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than for fiscal years beginning after December 15, 2020. The Company does not expect a material impact to its consolidated financial statements as a result of this guidance. Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options The FASB has issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2021-04 provides guidance that an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. The standard also provides guidance on how an entity should measure and recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified. The amendments in this ASU are effective for the Company for fiscal years beginning after December 15, 2021. Early adoption is permitted for all entities, including adoption in an interim period. The Company does not expect a material impact to its consolidated financial statements as a result of this guidance.

Business Combination (Tables)

Business Combination (Tables)	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Summary of net proceeds from the Business Combination	The following table summarizes the elements of the net proceeds from the Business Combination: Recapitalization Cash - RACA Trust and cash (net of redemptions) 121,770,367 Cash - PIPE Financing 165,000,000 Less: Underwriting fees, costs incurred by RACA and other direct and incremental costs, each paid prior to September 30, 2021 (21,887,685) Net proceeds from the Business Combination, net of costs incurred by RACA and direct and incremental costs paid per the statement of cash flows 264,882,682
Summary of number of shares of common stock outstanding immediately following the consummation of the Business Combination	The following table summarizes the number of shares of Common Stock outstanding immediately following the consummation of the Business Combination: Number of RACA Class A and Class B shares outstanding prior to the Business Combination 16,039,769 Class A shares issued pursuant to the PIPE Financing 16,500,000 Business Combination and PIPE Financing shares as converted into Common Stock 32,539,769 Conversion of POINT Biopharma Inc. common shares into Common Stock 57,582,025 Total shares of POINT Biopharma Global Inc. Common Stock outstanding immediately following the Business Combination 90,121,794

Prepaid expenses and other cu_2

Prepaid expenses and other current assets (Tables)	9 Months Ended
	Sep. 30, 2021
Prepaid Expense and Other Assets, Current [Abstract]
Summary of prepaid expenses and other current assets	Prepaid expenses and other current assets consisted of the following: As of September 30, 2021 As of December 31, 2020 $ $ Insurance 3,103,769 — Prepaid clinical trial expenses 2,548,625 1,763,731 Deposit on production equipment 594,143 — Canadian harmonized sales tax receivable 48,621 58,982 Other 173,061 27,633 Total 6,468,219 1,850,346

Accrued expenses (Tables)

Accrued expenses (Tables)	9 Months Ended
	Sep. 30, 2021
Accrued Liabilities, Current [Abstract]
Summary of accrued liabilities	Accrued liabilities consisted of the following: As of September 30, 2021 As of December 31, 2020 $ $ Accrued personnel costs 2,142,189 540,292 Accrued research and development costs 1,992,670 597,994 Accrued costs for purchases of property, plant and equipment 112,236 — Accrued corporate legal fees and other professional services 253,221 210,099 Other accrued costs 173,950 130,656 Total 4,674,266 1,479,041

Property, plant and equipment_2

Property, plant and equipment, net (Tables)	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Summary of property, plant and equipment, net	Property, plant and equipment, net consisted of the following: As of September 30, 2021 As of December 31, 2020 $ $ Property in development 15,816,792 9,797,400 Machinery and equipment 1,395,544 — Furniture and fixtures 591,652 — Computer equipment 97,991 — Total 17,901,979 9,797,400

Stock-based compensation (Table

Stock-based compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Summary of stock option activity	See Note 3 for additional details: Number of Weighted Weighted- Outstanding as of December 31, 2020 2,364,010 2.88 Granted 1,363,683 8.08 Exercised (64,570) 6.97 Forfeited (36,872) 7.01 Outstanding as of September 30, 2021 3,626,251 4.72 5.4 Vested and expected to vest as of September 30, 2021 3,626,251 4.72 5.4 Options exercisable as of September 30, 2021 985,145 4.51 6.3
Summary of assumptions used in the Black-Scholes-Merton option-pricing model to determine the grant date fair value of stock options granted	The following table presents the assumptions used in the Black-Scholes-Merton option-pricing model to determine the grant date fair value of stock options granted: Three months ended September 30, 2021 Three months ended September 30, 2020 Nine months ended September 30, 2021 Nine months ended September 30, 2020 Risk-free interest rate 0.664% 0.184% - 0.249% 0.664% - 0.716% 0.184% - 0.504% Expected term (in years) 4.25 3.08 - 4.25 4.25 - 5.38 3.08 - 4.25 Expected volatility 73% 65% 65% - 73% 65% Expected dividend yield —% —% —% —%

Net loss per share (Tables)

Net loss per share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Summary of basic and diluted net loss per share	Three months ended September 30, 2021 Three months ended September 30, 2020 Nine months ended September 30, 2021 Nine months ended September 30, 2020 Net loss attributable to common stockholders 17,116,632 3,047,250 31,705,711 7,822,081 Weighted-average common shares outstanding-basic and diluted 90,121,794 54,181,325 68,317,492 33,579,905 Net loss per share attributable to common stockholders-basic and diluted $ 0.19 $ 0.06 $ 0.46 $ 0.23

Related party transaction (Tabl

Related party transaction (Tables)	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Schedule of related party transactions	The Company recognized expenses in connection with related party transactions in the unaudited condensed consolidated statements of operations as follows: Three months ended September 30, 2021 Three months ended September 30, 2020 Nine months ended September 30, 2021 Nine months ended September 30, 2020 $ $ $ $ Stock-based compensation for consulting arrangement — — — 1,109,776 Consulting fees to stockholder — 12,029 — 172,720 Consulting fees on business activities to Board member 143,668 29,782 227,546 86,151 Reimbursement to Board member for occupancy costs 18,285 5,564 55,104 5,564 Total 161,953 47,375 282,650 1,374,211

Nature of business - Narrative

Nature of business - Narrative (Details)	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2021subsidiary$ / shares	Jun. 30, 2021$ / shares	Dec. 31, 2020$ / shares
Nature Of Business [Line Items]
Common shares, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.001	$ 0.0001
Number of wholly-owned subsidiaries | subsidiary		4
Private Placement
Nature Of Business [Line Items]
Sale of stock, price per share (in dollars per share)	$ 10	$ 10
Sale of stock, consideration received on transaction | $	$ 165,000,000
Class A common shares
Nature Of Business [Line Items]
Common shares, par value (in dollars per share)	$ 0.0001	0.0001
Class A common shares | Private Placement
Nature Of Business [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares	16,500,000
Class B common shares
Nature Of Business [Line Items]
Common shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
RACA
Nature Of Business [Line Items]
Business combination, entity shares issued per acquiree share (in shares) | shares	3.59
Exchange of common stock per share (in dollars per share)	$ 0.0001

Business Combination (Details)

Business Combination (Details)	Jun. 30, 2021USD ($)shares	Sep. 30, 2021USD ($)shares	Dec. 31, 2020shares
Business Acquisition [Line Items]
Exchange ratio	3.59	3.59
Number of common share of the company (in shares) | shares	1
Common stock, shares issued (in shares) | shares	90,121,794	90,121,794	54,647,656
Common stock, shares outstanding (in shares) | shares	90,121,794	90,121,794	54,647,656
Net proceeds excluding transaction costs	$ 4,700,000
Decrease in transaction costs		$ 300,000
POINT Biopharma Inc
Business Acquisition [Line Items]
Implied vested equity value	585,000,000
PIPE Financing	$ 165,000,000
Number of common shares received for each share (in shares) | shares	16,500,000
Common stock, shares outstanding (in shares) | shares	90,121,794
Goodwill	$ 0
Other intangible assets	0
Acquisition related costs	$ 21,900,000

Business Combination - Summary

Business Combination - Summary of Net proceeds (Details) - POINT Biopharma Inc	Jun. 30, 2021USD ($)
Business Acquisition [Line Items]
Cash - RACA Trust and cash (net of redemptions)	$ 121,770,367
Cash - PIPE Financing	165,000,000
Less: Underwriting fees, costs incurred by RACA and other direct and incremental costs, each paid prior to September 30, 2021	(21,887,685)
Net proceeds from the Business Combination, net of costs incurred by RACA and direct and incremental costs paid per the statement of cash flows	$ 264,882,682

Business Combination - Summar_2

Business Combination - Summary of Shares of Common Stock Issued (Details) - shares	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Total shares of POINT Biopharma Global Inc. Common Stock outstanding immediately following the Business Combination (in shares)	90,121,794	90,121,794	54,647,656
POINT Biopharma Inc
Business Acquisition [Line Items]
RACA Class A and Class B shares outstanding prior to the Business Combination (in shares)		16,039,769
Class A shares issued pursuant to the PIPE Financing (in shares)		16,500,000
Business Combination and PIPE Financing shares as converted into Common Stock (in shares)		32,539,769
Conversion of POINT Biopharma Inc. common shares into Common Stock (in shares)		57,582,025
Total shares of POINT Biopharma Global Inc. Common Stock outstanding immediately following the Business Combination (in shares)		90,121,794

Prepaid expenses and other cu_3

Prepaid expenses and other current assets (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Insurance	$ 3,103,769	$ 0
Prepaid clinical trial expenses	2,548,625	1,763,731
Deposit on production equipment	594,143	0
Canadian harmonized sales tax receivable	48,621	58,982
Other	173,061	27,633
Total	$ 6,468,219	$ 1,850,346

Accrued expenses (Details)

Accrued expenses (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Accrued Liabilities, Current [Abstract]
Accrued personnel costs	$ 2,142,189	$ 540,292
Accrued research and development costs	1,992,670	597,994
Accrued costs for purchases of property, plant and equipment	112,236	0
Accrued corporate legal fees and other professional services	253,221	210,099
Other accrued costs	173,950	130,656
Total	$ 4,674,266	$ 1,479,041

Property, plant and equipment_3

Property, plant and equipment, net (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 17,901,979	$ 9,797,400
Property in development
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	15,816,792	9,797,400
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	1,395,544	0
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	591,652	0
Computer equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 97,991	$ 0

Mortgage payable (Details)

Mortgage payable (Details)	Jul. 10, 2020USD ($)ft²	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)
Debt Instrument [Line Items]
Mortgage loan obtained	$ 3,562,500
Square-foot of building | ft²	80,000
Costs and fees incurred that are capitalized and recorded as finance costs over the life of the Mortgage	$ 17,194
Interest costs		$ 8,590	$ 25,462	$ 63,195
Amortization of debt issuance costs		$ 6,178	$ 2,507	$ 11,840	$ 2,507
LIBOR
Debt Instrument [Line Items]
Spread on variable rate	2.85%
LIBOR floor	0.25%

Stockholders' equity (Details)

Stockholders' equity (Details)	3 Months Ended				9 Months Ended
	Sep. 30, 2021$ / sharesshares	Sep. 30, 2020shares	Jun. 30, 2020shares	Mar. 31, 2020shares	Sep. 30, 2021USD ($)vote$ / sharesshares	Sep. 30, 2020USD ($)shares	Jun. 30, 2021$ / sharesshares	Mar. 31, 2021shares	Dec. 31, 2020$ / sharesshares	Dec. 31, 2019shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, authorized (in shares)	430,000,000				430,000,000				430,000,000
Common shares, par value (in dollars per share) | $ / shares	$ 0.0001				$ 0.0001		$ 0.001		$ 0.0001
Exchange ratio	3.59				3.59		3.59
Proceeds from issuance of common stock and warrants | $					$ 20,450,000
Common stock, shares issued (in shares)	90,121,794				90,121,794		90,121,794		54,647,656
Common stock, shares outstanding (in shares)	90,121,794				90,121,794		90,121,794		54,647,656
Preferred stock, shares Issued (in shares)	0				0				0
Preferred stock, shares outstanding (in shares)	0				0				0
Number of votes per share | vote					1
Cash dividend declared | $					$ 0	$ 0
Cash dividend paid | $					$ 0	$ 0
POINT Biopharma Inc
Accumulated Other Comprehensive Income (Loss) [Line Items]
Business combination and PIPE financing shares as converted into common stock (in shares)							32,539,769
Common stock, shares outstanding (in shares)							90,121,794
Stock options
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)					64,570
Preferred shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred shares, shares authorized (in shares)	20,000,000				20,000,000
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001				$ 0.0001
Number of shares issued during period (in shares)					0	0
Common Stock
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)	0	2,212,896	29,724,514	22,710,246	800,000
Common stock, shares outstanding (in shares)	90,121,794	54,647,656	52,434,760	22,710,246	90,121,794	54,647,656	90,121,794	57,582,025	54,647,656	0
Common Stock | Non-employee consultant
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)					18,000
Warrants
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)					2,869,799

Stock-based compensation - Narr

Stock-based compensation - Narrative (Details)	3 Months Ended			9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares	Mar. 31, 2021shares	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exchange ratio	3.59			3.59		3.59
Unvested stock options, vested (in shares)				269,043
Proceeds from issuance of common shares | $				$ 264,882,682
Unrecognized share-based compensation expense | $	$ 5,486,152			$ 5,486,152
Unrecognized share-based compensation expense, weighted average remaining vesting period				2 years 7 months 6 days
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of shares of Common Stock in connection with stock option exercises (in shares)		64,570		64,570
Vesting immediately upon grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage				25.00%
Vesting on 1st year anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	25.00%		25.00%	10.00%
Vesting ratably over the remaining three years
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	75.00%		75.00%		75.00%
Non-employee consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of common shares | $				$ 450,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)				1,363,683	2,129,048
Issuance of shares of Common Stock in connection with stock option exercises (in shares)				64,570
Stock options | Vesting on 1st year anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage					25.00%
Vesting period	3 years		3 years		3 years
Stock options | Vesting ratably 90 days after grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			90 days
Stock options | Non-employee consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)				358,724	1,734,453
Options granted in period, weighted average grant date fair value (in dollars per share) | $ / shares				$ 3.885	$ 0.701
Issuance of shares of Common Stock in connection with stock option exercises (in shares)				64,570
Intrinsic value | $				$ 0
Stock options | Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)	1,004,959		394,595	1,004,959	394,595
Options granted in period, weighted average grant date fair value (in dollars per share) | $ / shares	$ 4.697		$ 3.335
Stock options | Employee | Vesting ratably 90 days after grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)			125,553
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation | $	$ 222,135		$ 0	$ 1,650,804	$ 0
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation | $	$ 125,982		$ 403,997	$ 281,015	$ 1,619,048

Stock-based compensation - Summ

Stock-based compensation - Summarizes activity relating to options to purchase stock (Details) - Stock options	9 Months Ended
	Sep. 30, 2021$ / sharesshares	Sep. 30, 2020shares
Number of Shares
Outstanding as of December 31, 2020 (in shares) | shares	2,364,010
Granted (in shares) | shares	1,363,683	2,129,048
Exercised (in shares) | shares	(64,570)
Forfeited (in shares) | shares	(36,872)
Outstanding as of September 30, 2021(in shares) | shares	3,626,251
Weighted Average Exercise Price
Outstanding as of December 31, 2020 (in dollars per share) | $ / shares	$ 2.88
Granted (in dollars per share) | $ / shares	8.08
Exercised (in dollars per share) | $ / shares	6.97
Forfeited (in dollars per share) | $ / shares	7.01
Outstanding as of September 30, 2021 (in dollars per share) | $ / shares	$ 4.72
Weighted- Average Remaining Contractual Term (in years)
Outstanding as of September 30, 2021 (in years)	5 years 4 months 24 days
Vested and expected to vest as of September 30, 2021 (in shares) | shares	3,626,251
Options exercisable as of September 30, 2021 (in shares) | shares	985,145
Vested and expected to vest as of September 30, 2021 (in dollars per share) | $ / shares	$ 4.72
Options exercisable as of September 30, 2021 (in dollars per share) | $ / shares	$ 4.51
Vested and expected to vest as of September 30, 2021 (in years)	5 years 4 months 24 days
Options exercisable as of September 30, 2021 (in years)	6 years 3 months 18 days

Stock-based compensation - Assu

Stock-based compensation - Assumptions used in Black-Scholes-Merton option-pricing model (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.00664%
Expected term (in years)	4 years 3 months
Expected volatility	0.73%	0.65%		0.65%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		0.00184%	0.00664%	0.00184%
Expected term (in years)		3 years 29 days	4 years 3 months	3 years 29 days
Expected volatility			0.65%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		0.00249%	0.00716%	0.00504%
Expected term (in years)		4 years 3 months	5 years 4 months 17 days	4 years 3 months
Expected volatility			0.73%

Commitments and contingencies -

Commitments and contingencies - Property in development commitment (Details) - Property, in development commitment - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Other Commitments [Line Items]
Future payments relating to the construction and retrofit of the building	$ 4.1		$ 4.1
Total aggregate remaining minimum commitment	$ 0.8	$ 2.3	$ 5.7	$ 2.4

Commitments and contingencies_2

Commitments and contingencies - Clinical trial and commercial commitments & License agreements (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2021CAD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021EUR (€)
License agreements
Long-term Purchase Commitment [Line Items]
Aggregate milestone payments	$ 127,000		$ 127,000			€ 110,000
Aggregate minimum royalty payments	8,200,000		$ 8,200,000			7,120,000
Term of agreement			8 years	8 years
Aggregate minimum royalty payments | €						€ 6,300,000
License agreements | Research and development
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment	4,000,000	$ 400,000	$ 4,900,000		$ 1,400,000
Third Amendment | Research and development
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment	3,250,000		3,250,000
Supply agreements in connection with clinical trials
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment			$ 7,400,000
Supply agreements in connection with clinical trials | Minimum
Long-term Purchase Commitment [Line Items]
Term for total aggregate remaining minimum commitment			3 years	3 years
Supply agreements in connection with clinical trials | Maximum
Long-term Purchase Commitment [Line Items]
Minimum purchase commitments			$ 3,800,000
Term for total aggregate remaining minimum commitment			8 years	8 years
Supply agreements in connection | Research and development
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment	1,100,000	100,000	$ 2,400,000		100,000
Supply agreement to purchase certain products
Long-term Purchase Commitment [Line Items]
Minimum purchase commitments			49,500,000	$ 62.9
Agreement in connection
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment	0	0	0		0
Agreement in connection with the SPLASH clinical phase study
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment			47,700,000
Agreement in connection with the SPLASH clinical phase study | Research and development
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment	$ 3,900,000	$ 800,000	$ 6,900,000		$ 1,000,000
Agreement in connection with the SPLASH clinical phase study | Minimum
Long-term Purchase Commitment [Line Items]
Term for total aggregate remaining minimum commitment			1 year	1 year
Agreement in connection with the SPLASH clinical phase study | Maximum
Long-term Purchase Commitment [Line Items]
Term for total aggregate remaining minimum commitment			6 years	6 years

Net loss per share - Narrative

Net loss per share - Narrative (Details)	Sep. 30, 2021	Jun. 30, 2021
Earnings Per Share [Abstract]
Exchange ratio	3.59	3.59

Net loss per share - Summary of

Net loss per share - Summary of basic and diluted net loss per share (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Net loss attributable to common stockholders	$ 17,116,632	$ 8,804,658	$ 5,784,421	$ 3,047,250	$ 3,191,997	$ 1,582,834	$ 31,705,711	$ 7,822,081
Weighted-average common shares outstanding - basic (in shares)	90,121,794			54,181,325			68,317,492	33,579,905
Weighted-average common shares outstanding - diluted (in shares)	90,121,794			54,181,325			68,317,492	33,579,905
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ 0.19			$ 0.06			$ 0.46	$ 0.23
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ 0.19			$ 0.06			$ 0.46	$ 0.23

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Deferred income taxes	$ 81,044	$ 0	$ 245,251	$ 73,505
Uncertain tax positions	$ 0		$ 0		$ 0

Related party transactions - Sc

Related party transactions - Schedule of Related Party Transactions (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Related Party Transaction [Line Items]
Related party expenses	$ 161,953	$ 47,375	$ 282,650	$ 1,374,211
Stock-based compensation for consulting arrangement
Related Party Transaction [Line Items]
Related party expenses	0	0	0	1,109,776
Consulting fees to stockholder
Related Party Transaction [Line Items]
Related party expenses	0	12,029	0	172,720
Consulting fees on business activities to Board member
Related Party Transaction [Line Items]
Related party expenses	143,668	29,782	227,546	86,151
Reimbursement to Board member for occupancy costs
Related Party Transaction [Line Items]
Related party expenses	$ 18,285	$ 5,564	$ 55,104	$ 5,564

Related party transactions -Nar

Related party transactions -Narrative (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Amount due to related party	$ 0
Accrued liabilities	4,674,266	$ 1,479,041
Rent expense with related party	6,000
Director
Related Party Transaction [Line Items]
Accrued liabilities	$ 117,526